Treatment of lung cancer

肺癌的治疗

• 批准号: 7122536
• 负责人: DERICK LAU
• 金额: $ 11.89万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-15 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7122536
• 关键词: antineoplastics; carboplatin; clinical research; clinical trial phase II; combination cancer therapy; combinatorial chemistry; dosage; enzyme linked immunosorbent assay; high throughput technology; human subject; human therapy evaluation; hypoxia inducible factor 1; immunocytochemistry; ligands; light microscopy; neoplasm /cancer radiation therapy; nonsmall cell lung cancer; paclitaxel; patient oriented research; pharmacokinetics; plasminogen activator inhibitors; tirapazamine; vascular endothelial growth factors

DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer death in the United States. The candidate has devoted to clinical and translational research of lung cancer with the hope of improving outcomes for this devastating disease. An area of accomplishment is in the treatment with chemoradiotherapy for poor-risk patients with lung cancer. Another area of expertise of the investigator is in capitalizing the radiosensitizing and antiangiogenic properties of taxol for improving chemoradiotherapy of non-small-cell lung cancer (NSCLC). The candidate was the first researcher to report the in vivo antiangiogenic property of taxol. Clinical trials have demonstrated the feasibility and efficacy of twice-weekly taxol and carboplatin with concurrent radiation for stage III NSCLC. In basic and translational research, the candidate has identified peptide ligands specific for surface receptors of lung cancer cells using the technology of combinatorial chemistry and cell-growth-on-bead assay. A pilot study is being supported by a R21 grant to test the feasibility of using these peptides to capture cancer cells from malignant pleural effusion. The candidate is applying for a K-24 award to support his endeavor of achieving the following aims: 1. To conduct a NCI-sponsored phase II trial in the California Cancer Consortium to test the tolerance and efficacy of tirapazamine in combination with the previously established regimen of twice-weekly taxol and carboplatin with concurrent radiation for stage III NSCLC. A correlative study will explore the feasibility of measuring plasma hypoxia-induced proteins, plasminogen activator inhibitor type I (PAl-l) and vascular endothelial growth factor (VEGF), in association with tumor response before and after chemoradiotherapy. 2. To further develop the peptide-bead technology as a high-yield and high-throughput clinical procedure for isolating and enriching lung cancer cells from pleural fluid. This technology may facilitate the diagnosis of lung cancer. 3. To identify novel peptide ligands specific for lung cancer. The long-term goal is to develop these peptide ligands as molecularly targeted therapy for lung cancer. 4. To recruit and train hematology and oncology specialists in clinical research of cancer therapy.

描述（由申请人提供）：肺癌是美国癌症死亡的主要原因。 该候选人致力于肺癌的临床和翻译研究，希望改善这种毁灭性疾病的结果。 成就领域正在接受化学疗法治疗肺癌患者的化学疗法。 研究人员的另一个专业知识是利用紫杉醇的放射敏化和抗血管生成特性，用于改善非小细胞肺癌（NSCLC）的化学放疗。 该候选人是第一位报告紫杉醇体内抗血管生成特性的研究人员。 临床试验证明了两次每周两次的紫杉醇和卡泊素的可行性和功效，以及同时辐射III NSCLC。 在基本和转化研究中，候选者使用组合化学和细胞生长珠子测定法鉴定了针对肺癌细胞表面受体的肽配体。 R21赠款正在支持一项试点研究，以测试使用这些肽从恶性胸腔积液中捕获癌细胞的可行性。 该候选人正在申请K-24奖，以支持他实现以下目的的努力：1。在加利福尼亚癌症联盟中进行NCI赞助的II期试验，以测试Tirapazamine与先前确定的两次周期分类型和carboplatin contecrent contecrent contercrent contercrent III III III III III III III III III III III III III III III III III III III III III III III III III III III III III III III III III III III III III III的耐受性和功效。 一项相关研究将探讨测量血浆低氧诱导的蛋白质，纤溶酶原激活剂I型（PAL-L）和血管内皮生长因子（VEGF）的可行性，以及化学放疗前后的肿瘤反应。 2。为了进一步开发肽珠技术，作为一种高收益和高通量临床程序，用于分离和富集胸膜液中的肺癌细胞。该技术可能有助于诊断肺癌。 3。鉴定针对肺癌特异的新型肽配体。长期目标是将这些肽配体作为分子靶向肺癌的疗法。 4。招募和训练癌症治疗临床研究的血液学和肿瘤学专家。